Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.

Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG.

Oral Oncol. 2019 Oct 21:104440. doi: 10.1016/j.oraloncology.2019.104440. [Epub ahead of print] No abstract available.

PMID:
31648864
2.

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.

Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE.

Mol Pharmacol. 2019 Dec;96(6):862-870. doi: 10.1124/mol.119.117804. Epub 2019 Sep 25.

PMID:
31554698
3.

Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies.

Hinz TK, Heasley LE.

Semin Cancer Biol. 2019 Sep 20. pii: S1044-579X(19)30288-3. doi: 10.1016/j.semcancer.2019.09.014. [Epub ahead of print] Review.

PMID:
31546009
4.

Effectors of the spindle assembly checkpoint are confined within the nucleus of Saccharomyces cerevisiae.

Heasley LR, DeLuca JG, Markus SM.

Biol Open. 2019 Jun 12;8(6). pii: bio037424. doi: 10.1242/bio.037424.

5.

Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs.

Sisler DJ, Heasley LE.

Future Med Chem. 2019 May;11(10):1083-1086. doi: 10.4155/fmc-2018-0292. Epub 2019 May 14. No abstract available.

6.

STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.

Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD.

J Natl Cancer Inst. 2019 Dec 1;111(12):1339-1349. doi: 10.1093/jnci/djz036.

PMID:
30863843
7.

Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses.

Gurule NJ, Heasley LE.

Cancer Drug Resist. 2018;1:118-125. doi: 10.20517/cdr.2018.12. Epub 2018 Sep 19.

8.

Subcellular Localization and Activity of the Mitogen-Activated Protein Kinase Kinase 7 (MKK7) γ Isoform are Regulated through Binding to the Phosphatase Calcineurin.

Gibson ES, Woolfrey KM, Li H, Hogan PG, Nemenoff RA, Heasley LE, Dell'Acqua ML.

Mol Pharmacol. 2019 Jan;95(1):20-32. doi: 10.1124/mol.118.113159. Epub 2018 Nov 7.

PMID:
30404891
9.

Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.

Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR.

Clin Lung Cancer. 2019 Jan;20(1):e39-e51. doi: 10.1016/j.cllc.2018.09.001. Epub 2018 Sep 7.

10.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.

Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.

Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28.

11.

Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD.

Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. doi: 10.1158/1078-0432.CCR-18-1038. Epub 2018 Jul 24.

12.

Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.

Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA.

Cancer Res. 2018 Sep 1;78(17):4971-4983. doi: 10.1158/0008-5472.CAN-17-3822. Epub 2018 Jul 11.

13.

Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.

Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD.

Mol Cancer Ther. 2018 Sep;17(9):2049-2059. doi: 10.1158/1535-7163.MCT-17-1163. Epub 2018 Jul 3.

14.

Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.

Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD.

Clin Cancer Res. 2018 Sep 15;24(18):4539-4550. doi: 10.1158/1078-0432.CCR-18-0327. Epub 2018 May 30.

15.

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.

Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC.

Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6.

16.
17.

Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.

Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, Heasley L, Clambey E, Nemenoff R, Karam SD.

Oncoimmunology. 2017 Aug 3;6(10):e1356153. doi: 10.1080/2162402X.2017.1356153. eCollection 2017.

18.

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.

19.

Analysis of Drug Resistance Using Kinome-Wide Functional Screens.

Singleton KR, Earley KT, Heasley LE.

Methods Mol Biol. 2017;1636:163-177. doi: 10.1007/978-1-4939-7154-1_11.

PMID:
28730479
20.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR.

Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19.

21.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

22.

Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.

Ohm AM, Tan AC, Heasley LE, Reyland ME.

Oncogene. 2017 Jul 27;36(30):4370-4378. doi: 10.1038/onc.2017.27. Epub 2017 Apr 3.

23.

"Wait anaphase" signals are not confined to the mitotic spindle.

Heasley LR, Markus SM, DeLuca JG.

Mol Biol Cell. 2017 May 1;28(9):1186-1194. doi: 10.1091/mbc.E17-01-0036. Epub 2017 Mar 15.

24.

Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.

Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ.

Oncogenesis. 2017 Jan 16;6(1):e287. doi: 10.1038/oncsis.2016.89.

25.

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.

Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.

Clin Transl Sci. 2016 Dec;9(6):293-301. doi: 10.1111/cts.12413. Epub 2016 Oct 20.

26.

Small molecule perturbations of septins.

Heasley LR, McMurray MA.

Methods Cell Biol. 2016;136:311-9. doi: 10.1016/bs.mcb.2016.03.013. Epub 2016 Apr 13.

PMID:
27473917
27.

Kinetic partitioning during de novo septin filament assembly creates a critical G1 "window of opportunity" for mutant septin function.

Schaefer RM, Heasley LR, Odde DJ, McMurray MA.

Cell Cycle. 2016 Sep 16;15(18):2441-53. doi: 10.1080/15384101.2016.1196304. Epub 2016 Jul 11.

28.

MERTK as a novel therapeutic target in head and neck cancer.

von Mässenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F, Brossart P, Kirfel J, Heasley L, Brägelmann J, Perner S.

Oncotarget. 2016 May 31;7(22):32678-94. doi: 10.18632/oncotarget.8724.

29.

Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

von Mässenhausen A, Deng M, Billig H, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Göke F, Franzen A, Heasley L, Kirfel J, Brägelmann J, Perner S.

Target Oncol. 2016 Oct;11(5):631-642.

PMID:
27053219
30.

Assembly, molecular organization, and membrane-binding properties of development-specific septins.

Garcia G 3rd, Finnigan GC, Heasley LR, Sterling SM, Aggarwal A, Pearson CG, Nogales E, McMurray MA, Thorner J.

J Cell Biol. 2016 Feb 29;212(5):515-29. doi: 10.1083/jcb.201511029.

31.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC.

BMC Genomics. 2015;16 Suppl 12:S2. doi: 10.1186/1471-2164-16-S12-S2. Epub 2015 Dec 9.

32.

Roles of septins in prospore membrane morphogenesis and spore wall assembly in Saccharomyces cerevisiae.

Heasley LR, McMurray MA.

Mol Biol Cell. 2016 Feb 1;27(3):442-50. doi: 10.1091/mbc.E15-10-0721. Epub 2015 Dec 17.

33.

Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA.

Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. doi: 10.1158/1940-6207.CAPR-15-0305. Epub 2015 Nov 5.

34.

A Short CEP135 Splice Isoform Controls Centriole Duplication.

Dahl KD, Sankaran DG, Bayless BA, Pinter ME, Galati DF, Heasley LR, Giddings TH Jr, Pearson CG.

Curr Biol. 2015 Oct 5;25(19):2591-6. doi: 10.1016/j.cub.2015.08.039. Epub 2015 Sep 24.

35.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.

Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.

36.

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.

Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC.

Bioinformatics. 2015 Dec 1;31(23):3799-806. doi: 10.1093/bioinformatics/btv427. Epub 2015 Jul 23.

37.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

38.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S.

Clin Cancer Res. 2015 Oct 1;21(19):4356-64. doi: 10.1158/1078-0432.CCR-14-3357. Epub 2015 May 26.

39.

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE.

PLoS One. 2015 May 6;10(5):e0123600. doi: 10.1371/journal.pone.0123600. eCollection 2015.

40.

FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area.

von Mässenhausen A, Franzen A, Heasley L, Perner S.

Ann Transl Med. 2013 Oct;1(3):23. doi: 10.3978/j.issn.2305-5839.2013.06.08.

41.

Off-target effects of the septin drug forchlorfenuron on nonplant eukaryotes.

Heasley LR, Garcia G 3rd, McMurray MA.

Eukaryot Cell. 2014 Nov;13(11):1411-20. doi: 10.1128/EC.00191-14. Epub 2014 Sep 12.

42.

Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE.

Mol Cancer Res. 2014 Oct;12(10):1460-9. doi: 10.1158/1541-7786.MCR-14-0038. Epub 2014 Jun 25.

43.

Hypoxia regulates alternative splicing of HIF and non-HIF target genes.

Sena JA, Wang L, Heasley LE, Hu CJ.

Mol Cancer Res. 2014 Sep;12(9):1233-43. doi: 10.1158/1541-7786.MCR-14-0149. Epub 2014 May 21.

44.

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC.

Bioinformatics. 2014 Sep 1;30(17):2393-8. doi: 10.1093/bioinformatics/btu323. Epub 2014 May 7.

45.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

46.

Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma.

Schröck A, Bode M, Göke FJ, Bareiss PM, Schairer R, Wang H, Weichert W, Franzen A, Kirsten R, van Bremen T, Queisser A, Kristiansen G, Heasley L, Bootz F, Lengerke C, Perner S.

Carcinogenesis. 2014 Jul;35(7):1636-42. doi: 10.1093/carcin/bgu094. Epub 2014 Apr 17.

PMID:
24743512
47.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.

PLoS One. 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236. eCollection 2013.

48.

Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer.

Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA.

PLoS One. 2013 Oct 18;8(10):e76895. doi: 10.1371/journal.pone.0076895. eCollection 2013.

49.

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S.

Digestion. 2013;88(3):172-81. doi: 10.1159/000355018. Epub 2013 Oct 17.

50.

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.

Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schröck A, Perner S.

Mod Pathol. 2013 Oct;26(10):1298-306. doi: 10.1038/modpathol.2013.58. Epub 2013 Apr 26.

Supplemental Content

Loading ...
Support Center